Claims
- 1. A method of treating or improving healing comprising administering to a subject an effective amount of an agonist or antagonist of IL-23.
- 2. The method of claim 1 wherein the agonist or antagonist comprises:
a) a polypeptide of IL-23, or a derivative or variant thereof; b) a binding composition derived from an antibody that specifically binds to IL-23 or to IL-23R; or c) a nucleic acid encoding a polypeptide of IL-23, or a derivative or variant thereof.
- 3. The method of claim 2, wherein the derivative or variant comprises an IL-23 hyperkine.
- 4. The method of claim 1, wherein the agonist comprises a complex of:
a) a mature sequence of SEQ ID NO: 10; and b) a mature sequence of SEQ ID NO: 12.
- 5. The method of claim 2, wherein the nucleic acid further comprises an expression vector.
- 6. The method of claim 1, wherein the healing is:
a) of a skin or cutaneous wound; b) of an ulcer or graft; or c) improper healing.
- 7. The method of claim 1, wherein the treating or improving increases:
a) a pressure required to break a healed or healing wound; b) a stiffness of a healed or healing wound; c) a rate of healing of a wound; d) a granulation layer thickness of a healed or healing wound; e) recruitment of a cell to or towards a wound; or f) antimicrobial activity.
- 8. The method of claim 7, wherein the cell is:
a) a CD11b+, MHC Class II+ cell; b) a monocyte/macrophage; or c) a CD31+ endothelial cell.
- 9. The method of claim 7, wherein the recruitment is in or towards a granulation tissue.
- 10. The method of claim 7, wherein:
a) the increased wound breaking pressure is about a 15% or about a 20% increase in wound breaking pressure; or b) the increased stiffness is about a 15% or about a 20% increase in stiffness.
- 11. The method of claim 1, wherein the treating or improving comprises increased:
a) angiogenesis; or b) immune surveillance.
- 12. The method of claim 11, wherein:
a) the increased angiogenesis is mediated by ICAM-1 or -2; or b) the increased immune surveillance is mediated by dendritic cells.
- 13. The method of claim 1, wherein the treating or improving comprises increased expression of a nucleic acid or protein of:
a) a cytokine in addition to IL-23; b) a signaling molecule; c) an anti-microbial molecule; d) a protease or protease inhibitor; or e) a molecule of the extracellular matrix.
- 14. The method of claim 13, wherein the cytokine nucleic acid or protein is IL-17, IL-6, IL-19, GRO-alpha, or GM-CSF.
- 15. The method of claim 13, wherein the gene or protein is:
a) lactoferrin; b) DEC-205; c) CD50; d) nitric oxide synthase; or e) secretory leukoprotease inhibitor; or f) CD40L.
- 16. The method of claim 1, wherein the antagonist comprises:
a) a nucleic acid; b) a blocking antibody to IL-23 or to IL-23R; or c) a soluble receptor derived from an extracellular part of IL-23R.
- 17. The method of claim 16, wherein the nucleic acid comprises:
a) an anti-sense nucleic acid; or b) interference RNA.
- 18. An agonist of IL-23 derived from the binding site of an antibody that specifically binds to an IL-23 receptor.
- 19. The agonist of claim 18 that is:
a) a polyclonal antibody; b) a monoclonal antibody; c) an Fab, Fv, or F(ab′)2 fragment; d) humanized; e) a peptide mimetic; or f) detectably labeled.
- 20. The agonist of claim 18, comprising a complex of:
a) a polypeptide of the mature sequence of SEQ ID NO: 10; and b) a polypeptide of the mature sequence of SEQ ID NO: 12.
- 21. The agonist of claim 18, comprising a complex of:
a) two polypeptides of the mature sequence of SEQ ID NO: 10; and b) two polypeptides of the mature sequence of SEQ ID NO: 12.
- 22. The agonist of claim 18, wherein contact of the agonist to a cell expressing hIL-23R and hIL-12beta1 results in an increase in proliferation of the cell.
- 23. A kit comprising the agonist of claim 18 and:
a) a compartment; or b) instructions for use or disposal.
Parent Case Info
[0001] This application claims benefit of U.S. Provisional Patent Application No. 60/436,274, filed Dec. 23, 2002.
Continuations (1)
|
Number |
Date |
Country |
Parent |
60436274 |
Dec 2002 |
US |
Child |
10742405 |
Dec 2003 |
US |